KR930000527A - 칼슘-길항성 물질로서의 이노시톨 포스페이트 동족체 - Google Patents
칼슘-길항성 물질로서의 이노시톨 포스페이트 동족체 Download PDFInfo
- Publication number
- KR930000527A KR930000527A KR1019920011075A KR920011075A KR930000527A KR 930000527 A KR930000527 A KR 930000527A KR 1019920011075 A KR1019920011075 A KR 1019920011075A KR 920011075 A KR920011075 A KR 920011075A KR 930000527 A KR930000527 A KR 930000527A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- aryl
- phosphate
- formula
- compound
- Prior art date
Links
- 229940127291 Calcium channel antagonist Drugs 0.000 title abstract 2
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 11
- 239000010452 phosphate Substances 0.000 claims abstract 11
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 15
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical class O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4081—Esters with cycloaliphatic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 일반식(I)의 화합물 및 생리학적으로 허용되는 이의 염.상기식에서, R1은 1)포스페이트 2)OH, 3)1,2디아실-sn-글리세르-3-일 포스페이트(여기서, 아실은 탄소수 2내지 20이고 C-C-이중 결합이 0 내지 4개인 지방산이다)이거나, 4)1,2디알킬sn-글리세르-3-일 포스페이트(여기서, 알킬은 탄소수 2내지 20이고 C-C-이중결합이 0내지 4개인 탄화수소이다)이며, R2는 1)OH, 또는 2) 포스페이트이고, R3은 1)포스페이트, 또는 2)OH, 3)일반식(II)의 라디칼(여기서 a) Y=Z=O 및 X=(C1-C8)-알킬, b) Y=Z=O 및 X=(C6-C18)-아릴, c) Y=S 및 Z=O 및 X=(C1-C8)-알킬, d) Y=S 및 Z=O 및 X=(C6-C18)-아릴, e) Y=O 및 Z=X-(C1-C8)-알킬, f) Y=O 및 Z=X=(C6-C18)-아릴, g) Y=S 및 Z=X=(C1-C8)-알킬, h) Y=S 및 Z=X=(C6-C18)=아릴, i) Y=Z=O 및 X=CF2H, j) Y=O 및 Z=X=F, k) Y=Z=O 및 X=O-(C1-C8)-알킬, l) Y=Z=O 및 X=O-(C6-C18)-아릴, m) Y=S 및 Z=O 및 X=O-(C6-C18)-알킬, n) Y=S 및 Z=O 및 X=O-(C6-C18)-아릴, o) Y=O 및 Z=X=O-(C6-C8)-알킬, p) Y=O 및 Z=X=O-(C6-C18)-아릴, q) Y=S 및 Z=X=O-(C1-C8)-알킬 및 r) Y=S 및 Z=X=O-(C6-C18)-아릴이다), 4) 일반식(III)의 라디칼[여기서, a) X=OR (여기서, R은 H, (C1-C8)-알킬, 또는 (C6-C18)-아릴이다), b) X=(C1-C8)-알킬, c) X=(C6-C18)-아릴, d) X=NH-(C1-C8)-알킬 및 e) X=NH-(C6-C18)-아릴이다], 및 5) 일반식(IV)의 라디칼[여기서, a) X=OR (여기서, R은 H, (C1-C8)-알킬, 또는 (C6-C18)-아릴이다), b) X=(C1-C8)-알킬, c) X=(C6-C18)-아릴, d) X=NH-(C1-C8)-알킬 및 e) X=NH-(C6-C18)-아릴이다]이며, R4는 1) 일반식(V)의 라디칼(여기서 a) Y=Z=O 및 X=(C1-C8)-알킬, b) Y=Z=O 및 X=(C6-C18)-아릴, c) Y=S 및 Z=O 및 X=(C1-C8)-알킬, d) Y=S 및 Z=O 및 X=(C6-C18)-아릴, e) Y=O 및 Z=X-(C1-C8)-알킬, f) Y=O 및 Z=X=(C6-C18)-아릴, g) Y=S 및 Z=X=(C1-C8)-알킬, h) Y=S 및 Z=X=(C6-C18)=아릴, i) Y=Z=O 및 X=CF2H, j) Y=O 및 Z=X=F, k) Y=Z=O 및 X=O-(C1-C8)-알킬, l) Y=Z=O 및 X=O-(C6-C18)-아릴, m) Y=S 및 Z=O 및 X=O-(C6-C18)-알킬, n) Y=S 및 Z=O 및 X=O-(C6-C18)-아릴, o) Y=O 및 Z=X=O-(C6-C8)-알킬, p) Y=O 및 Z=X=O-(C6-C18)-아릴, q) Y=S 및 Z=X=O-(C1-C8)-알킬 및 r) Y=S 및 Z=X=O-(C6-C18)-아릴이다), 2) 일반식(VI)의 라디칼[여기서, a) X=OR (여기서, R은 H, (C1-C8)-알킬, 또는 (C6-C18)-아릴이다), b) X=(C1-C8)-알킬, c) X=(C6-C18)-아릴, d) X=NH-(C1-C8)-알킬 및 e) X=NH-(C6-C18)-아릴이다] 및 3)일반식(VII)의 라디칼[여기서, a) X=OR (여기서, R은 H, (C1-C8)-알킬, 또는 (C6-C18)-아릴이다), b) X=(C1-C8)-알킬, c) X=(C6-C18)-아릴, d) X=NH-(C1-C8)-알킬 및 e) X=NH-(C6-C18)-아릴이다]이다.
- 제1항에 있어서, R1은 포스페이트 또는 1,2-디아실-sn-글리세르-3-일 포스페이트(여기서, 아실은 탄소수 2내지 20이고 C-C-이중 결합이 0 내지 4개인 지방산 라디칼이다)이고, R2는 OH, 또는 포스페이트이며, R3은 OH 또는 포스페이트이고, R4는 일반식의 라디칼 (여기서, Y=Z=O이고, X=(C1-C8)-알킬이다)인 일반식(I)의 화합물 및 생리학적으로 허용되는 이의 염.
- 제2항에 있어서, R4가 X가 메틸, 에틸 또는 프로필인 일반식(V)의 라디칼인 일반식(I)의 화합물.
- 미오-이노시톨 유도체로부터 출발하여 제1항에 내지 제3항중 어느 한 항에 따른 일반식(I)의 화합물을 제조하는 방법.
- 약물로서 사용하기 위한 제1항 내지 제3항중 어느 한 항에 따른 일반식(I)의 화합물.
- 심맥관계 질환 치료용 약물로서 사용하기 위한, 제1항 내지 제3항중 어느 한 항에 따른 일반식(I)의 화합물.
- 제1항에 따른 화합물 또는 생리학적으로 허용되는 이의 염의 유효량 및 생리학적으로 허용되는 비히클을 포함하는 약제학적 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91110546 | 1991-06-26 | ||
EP91110546.8 | 1991-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR930000527A true KR930000527A (ko) | 1993-01-15 |
Family
ID=8206868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920011075A KR930000527A (ko) | 1991-06-26 | 1992-06-25 | 칼슘-길항성 물질로서의 이노시톨 포스페이트 동족체 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5395828A (ko) |
EP (1) | EP0520372B1 (ko) |
JP (1) | JP3161813B2 (ko) |
KR (1) | KR930000527A (ko) |
AT (1) | ATE145911T1 (ko) |
CA (1) | CA2072303A1 (ko) |
DE (1) | DE69215588T2 (ko) |
DK (1) | DK0520372T3 (ko) |
ES (1) | ES2095985T3 (ko) |
GR (1) | GR3022546T3 (ko) |
HU (2) | HUT64081A (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2978995A (en) * | 1994-06-30 | 1996-01-25 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Methods for treating cell proliferative disorders by modulating signal transduction |
US6939857B2 (en) | 2000-05-12 | 2005-09-06 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
US6716826B2 (en) | 2000-05-12 | 2004-04-06 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
US6759390B2 (en) | 2000-05-12 | 2004-07-06 | Manuel Martin-Lomas | Compounds and their uses |
US6953781B2 (en) | 2000-05-12 | 2005-10-11 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
EP1331932B1 (en) * | 2000-11-09 | 2007-04-04 | Contrimmune Biotechnology Inc. | Use of xestospongin c for treating or preventing hiv infection |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4515722A (en) * | 1982-03-30 | 1985-05-07 | Merck & Co., Inc. | Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents |
US4952717A (en) * | 1986-03-11 | 1990-08-28 | Mitsui Toatsu Chemicals, Incorporated | Myoinositol derivatives and preparation process thereof |
SE8605063D0 (sv) * | 1986-11-26 | 1986-11-26 | Matti Siren | Derivatives of cyclohexane |
-
1992
- 1992-06-23 DE DE69215588T patent/DE69215588T2/de not_active Expired - Lifetime
- 1992-06-23 AT AT92110563T patent/ATE145911T1/de active
- 1992-06-23 ES ES92110563T patent/ES2095985T3/es not_active Expired - Lifetime
- 1992-06-23 DK DK92110563.1T patent/DK0520372T3/da active
- 1992-06-23 EP EP92110563A patent/EP0520372B1/en not_active Expired - Lifetime
- 1992-06-24 HU HU9202103A patent/HUT64081A/hu unknown
- 1992-06-24 US US07/903,485 patent/US5395828A/en not_active Expired - Lifetime
- 1992-06-25 CA CA002072303A patent/CA2072303A1/en not_active Abandoned
- 1992-06-25 KR KR1019920011075A patent/KR930000527A/ko active IP Right Grant
- 1992-06-25 JP JP16740192A patent/JP3161813B2/ja not_active Expired - Lifetime
-
1995
- 1995-06-28 HU HU95P/P00494P patent/HU211491A9/hu unknown
-
1997
- 1997-02-12 GR GR970400235T patent/GR3022546T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
HU9202103D0 (en) | 1992-10-28 |
HU211491A9 (en) | 1995-11-28 |
EP0520372A1 (en) | 1992-12-30 |
ATE145911T1 (de) | 1996-12-15 |
DE69215588T2 (de) | 1997-05-15 |
JP3161813B2 (ja) | 2001-04-25 |
US5395828A (en) | 1995-03-07 |
DE69215588D1 (de) | 1997-01-16 |
DK0520372T3 (da) | 1997-05-12 |
ES2095985T3 (es) | 1997-03-01 |
EP0520372B1 (en) | 1996-12-04 |
JPH05213975A (ja) | 1993-08-24 |
GR3022546T3 (en) | 1997-05-31 |
HUT64081A (en) | 1993-11-29 |
CA2072303A1 (en) | 1992-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT75649A (de) | Neue carbonsaeurederivate verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel | |
ATE89263T1 (de) | Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
KR890011601A (ko) | (사이클로알킬아미노)메틸렌비스(포스폰산)및 활성성분으로서 이를 함유한 의약 | |
ATE25974T1 (de) | Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung. | |
DE3778951D1 (de) | 1,2,5,6-tetrahydropyridin-3-carboxaldehydoximderivate, verfahren zur herstellung, sie enthaltende zusammensetzungen und deren anwendung als heilmittel. | |
ATE46696T1 (de) | 1- und 1,1-disubstituierte, 6-substituierte, 2carbamimidoyl-1-carbadethiapen-2-em-3carbons|uren, verfahren zur herstellung und diese enthaltende antibiotische zusammensetzung. | |
EP0193148A3 (en) | 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-(alkoxy-containing acyl)hydrazides | |
KR840007596A (ko) | 유기인 유도체의염의 제조방법 | |
KR940021059A (ko) | 지질 대사 개선제 | |
HUT55032A (en) | Process for producing 19-norsteroids comprising carbon chain substituted in 11beta position by amide or carbamagte group, as well as pharmaceutical compositions comprising such compounds as active ingredient | |
ATE25847T1 (de) | Derivate von pyridinium-thiomethylcephalosporinen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate. | |
DE69409337D1 (de) | Verzweigte Aminothiazole-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammenstellungen die sie enthalten | |
ATE64368T1 (de) | Ester von mit pyrethrumsaeure verwandten cyclopropancarbonsaeuren, verfahren zur ihrer herstellung und ihre verwendung als parasitizide. | |
AU6476394A (en) | 19-nor steroids having a phenoxyalkylsulphonamide or phenoxyalkylsulphonylurea chain in position 11beta, preparation process and intermediates, use as medicaments and pharmaceutical compositions containing them | |
KR900016098A (ko) | 카페인산의 유도체 및 이를 함유하는 약제학적 조성물 | |
DE59105219D1 (de) | Neue 4-Chinolyl-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln. | |
KR930000527A (ko) | 칼슘-길항성 물질로서의 이노시톨 포스페이트 동족체 | |
FR2663328B1 (fr) | Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant. | |
ATE135681T1 (de) | Diclofenac-cholinsalz, verfahren zur herstellung und pharmazeutische zusammensetzungen, die es enthalten | |
ATE166060T1 (de) | Neue (estradiol-derivat)-chlorambucil-konjugate, verfahren zu ihrer herstellung und pharmazeutische präparate | |
DE69711920D1 (de) | Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale | |
DE3866292D1 (de) | Piperazinylalkylpiperazindion-derivate, ihre verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen. | |
ATE162195T1 (de) | 4-hydroxy-phenyl-beta-d-glukose-monoester, verfahren zur ihrer herstellung und ihre verwendung in der kosmetik, der pharmazie, als zahnpflegemitteln und lebensmitteln | |
DE3866603D1 (de) | 1-benzoyl-2-oxo-5-alkoxy-pyrrolidin-derivate, ihre herstellung und verwendung als heilmittel und zubereitungen, die sie enthalten. | |
ATE34740T1 (de) | (bis(hydroxymethyl)methyl)-isochinolinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
NORF | Unpaid initial registration fee |